Patients with sAML have lower or similar expression levels of PD-L1 compared with MPN/MDS, with no difference between early and advanced stages of MDS; suggesting that the peak of PD-L1 expression results in a long-term suppression of the immune response that allows subsequent mutations to develop and trigger the progression to sAML [75]. Here, CD274 is linked to myeloproliferative neoplasm.